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Hematopoietic stem cell transplantation (HSCT) recipients are at risk for varicella-zoster virus (VZV) reac-
tivation. Vaccination may help restore VZV immunity; however, the available live attenuated VZV vaccine
(Zostavax) is contraindicated in immunocompromised hosts. We report our experience with using a single
dose of VZV vaccine in 110 adult autologous and allogeneic HSCT recipients who were about 2 years after
transplantation, free of graft-versus-host disease, and not receiving immunosuppression. One hundred eight
vaccine recipients (98.2%) had no clinically apparent adverse events with a median follow-up period of
9.5 months (interquartile range, 6 to 16; range, 2 to 28). Two vaccine recipients (1.8%) developed a skin rash
(one zoster-like rash with associated pain, one varicella-like) within 42 days post-vaccination that resolved
with antiviral therapy. We could not conﬁrm if these rashes were due to vaccine (Oka) or wild-type VZV. No
other possible cases of VZV reactivation have occurred with about 1178 months of follow-up. Live attenuated
zoster vaccine appears generally safe in this population when vaccinated as noted; the overall vaccination risk
needs to be weighed against the risk of wild-type VZV disease in this high-risk population.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) recipients
are at increased risk for varicella-zoster virus (VZV) reac-
tivation. VZV disease after HSCT varies depending on type of
transplantation (autologous versus allogeneic) but is reported
to be as high as 30% to 53%; the highest risk has been reported
to occur during the ﬁrst year after transplantation andmay be
associated with visceral dissemination [1-8]. Antiviral pro-
phylaxis has been shown to prevent VZV reactivation;
Table 1
Patient Baseline Characteristics
Characteristic Value
No. of patients 110
Median age, yr (IQR; range) 58.5 (49-64; 22-74)
Male sex (%) 66 (60.0)
Median months from transplantation (IQR; range) 27 (24-41; 21-98)
Median months of follow-up after vaccination
(IQR; range)
9.5 (6-16; 2-28)
HSCT indication
Lymphoma (%) 40 (36.4)
Leukemia (%) 30 (27.3)
Multiple myeloma (%) 27 (24.5)
Other* (%) 13 (11.8)
Type of stem cell transplantation
Allogeneic (%) 58 (52.7)
Autologous (%) 52 (47.3)
Pretransplant VZV serology
Positive 99 (90.1)
Equivocal 4 (3.6)
Negative 6 (5.4)
Unknown 1 (.9)
IQR indicates interquartile range.
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[1,3,9]. Evenwhen prolonged antiviral prophylactic strategies
are used, the incidence of VZV disease remains increased in
HSCT recipients, with increased risk for reactivation after
prophylaxis is discontinued [9-11]. In 1 study the incidence of
VZV in allogeneic HSCT recipients occurring after 12 months
of acyclovir prophylaxis was 5% by year 1 after HSCT, 21% by
year 2, 29% by year 3, and 37% by year 5 [3].
Boosting immunity against VZV after HSCT through
vaccination may help decrease the risk of reactivation.
However, limited data are available on the safety and
immunogenicity of licensed VZV vaccines in adult HSCT re-
cipients [12]. Guidelines [13,14] have recommend the use of
varicella vaccine (Varivax Merck & Co., INC, Whitehouse
Station, NJ) in HSCT recipients who have met criteria for live
virus vaccination. These recommendations are based on
expert opinion that assumes this vaccine, which has lower
viral titers compared with the zoster vaccine (Zostavax), may
be safer [13]. We report our experience using the zoster
vaccine in HSCT recipients.* Myelodysplastic syndrome (n ¼ 7), aplastic anemia (n ¼ 5), Walden-
ström’s macroglobulinemia (n ¼ 1).METHODS
As part of an update in vaccine guidelines in July 2011, autologous and
allogeneic HSCT recipients followed at Dana-Farber Cancer Institute were
considered for zoster vaccine if they were about 24 months after HSCT, free
of graft-versus-host disease (allogeneic), on no immunosuppression, and
not taking prophylactic antivirals (acyclovir, valacyclovir, or famciclovir).
The recommendation to use the zoster vaccine was made by a multidisci-
plinary team given the high risk of VZV reactivation in this population after
prophylaxis discontinuation and the increased morbidity from VZV in this
population, including the development of postherpetic neuralgia. This
recommendation followed the approach for administration of other live
attenuated vaccines such as the measles-mumps-rubella (MMR) vaccine.
Patients who met these criteria were given a single dose (0.65 mL) of
Zostavax (Merck & Co, INC, Whitehouse Station, NJ) containing a minimum
of 19,400 plaque-forming units administered subcutaneously at the
discretion of their treating physician. Patient’s characteristics were recor-
ded. We followed patients for at least 42 days after vaccination. Data were
collected through November 6, 2013. Adverse events were captured by
reviewing medical records and contacting the patients’ primary oncologists.
This study was approved by the Ofﬁce for Human Research Studies at Dana-
Farber/Harvard Cancer Center.RESULTS
One hundred ten patients received zoster vaccine be-
tween July 2011 and September 2013. Baseline characteris-
tics are summarized in Table 1. Fifty-eight patients (52.7%)
underwent allogeneic HSCT, and 52 patients (47.3%) under-
went autologous HSCT. Other characteristics are outlined in
Table 1.
Median follow-up time was 9.5 months (interquartile
range, 6 to 16; range, 2 to 28). One hundred eight patients
(98.2%) had no clinically apparent adverse events. Seventy-
six patients received MMR vaccine on the same day zoster
vaccine was administered. There were no reported cases of
VZV reactivation in any patient occurring after the initial
42 days post-vaccination or during follow-up (0 cases/1178
person-months). No graft-versus-host disease ﬂares were
noted in allogeneic HSCT recipients within 42 days post-
vaccination.
Two patients developed skin rashes within 42 days after
vaccination. Both patients had positive VZV serology before
transplantation. The ﬁrst patient, a 46-year-old woman who
underwent allogeneic HSCT 34 months before receiving
zoster vaccination in the left upper arm, developed a skin
rash 10 days after vaccination. Her absolute lymphocyte
count at the time of vaccination was 2.6 K/mL. No CD4 count
was performed before vaccination. She did not receive MMRvaccine on the same day. Her local physician reported a
dermatomal rash involving the right side of her chest. She
was treated with oral acyclovir. She developed postherpetic
neuralgia that required treatment with gabapentin. No
samples could be obtained to determine if the rash was due
to wild-type or vaccine virus. At a 6-month follow-up, the
neuralgia had markedly improved.
The second patient, a 38-year-old woman who under-
went autologous HSCT 25 months before receiving zoster
vaccination, had an absolute lymphocyte count at the time of
vaccination of 1.8 K/mL. No CD4 count was performed before
vaccination. She received MMR vaccine on the same day as
the zoster vaccine. She developed a vesicular skin rash
involving the upper extremities and the trunk 24 days after
vaccination. Her local physician diagnosed her with zoster
and prescribed a course of valacyclovir. No samples could be
obtained to conﬁrm if the rash was due to VZV or other
causes. At a 4-month follow-up visit she was well.DISCUSSION
Given the lack of data-driven recommendations in the
current guidelines for zoster vaccine in adults after HSCT, we
implemented a vaccine schedule that uses the zoster vaccine.
Based on the VZV incubationperiod and previously published
zoster vaccine studies, the ﬁrst 42 days after vaccination was
chosen as the primary safety risk assessment period [10,15].
One hundred eight HSCT recipients (98.2%) had no clinically
identiﬁable adverse events after vaccination. In the 2 patients
who developed a skin rash after vaccination, we could not
conﬁrm that the rash was caused by the vaccine strain. In the
ﬁrst patient, the rash developed 10 days after vaccination and
was consistent with zoster given dermatomal presentation
and ensuing postherpetic neuralgia. No additional cases of
zoster were identiﬁed after the 42 day post-vaccine window,
with 1178 months of follow up.
In the Zostavax Efﬁcacy and Safety Trial study [15] that
enrolled22,439 subjects, 34patients overall (.15%) had zoster-
like rashes (19 in the vaccine arm, 15 in the placebo arm)
within the 42-day post-vaccination reporting period. Wild-
type VZV was detected in 3 subjects in the vaccine group
and in 7 subjects in the placebo groups. TheOka strainwasnot
N.C. Issa et al. / Biol Blood Marrow Transplant 20 (2014) 279e287 287detected. Of the 124 cases (.55%) of varicella-like rashes re-
ported within 42-day post-vaccination, only 1 specimen had
VZV detected (zoster vaccine arm); however, it could not be
determined if it was a wild-type or vaccine virus. In the
Shingles Prevention Study study [10], 53 subjects of 38,546
enrolled (19,270 received vaccine, 19,276 received placebo)
hadzoster-like rashes (17vaccine, 36placebo).Wild-typeVZV
was detected in 25 specimens (5 in the vaccine group, 20 in
the placebo), and the Oka strain was not detected.
The incubation period for an Oka straineassociated
dermatomal herpes zoster seemed to be very short in our
ﬁrst patient. In previous studies, rash after vaccination due to
wild-type VZV occurred at a median of 8 days after vacci-
nation (range, 1 to 20), whereas Oka strainerelated rash
occurred at amedian of 21 days (range, 5 to 42) [10,16]. In our
second patient, the presentation suggested a varicella-like
rash. In clinical trials of Varivax conducted in VZV-
seronegative children, adolescent, and adults, the reported
incidence of varicella-like rash was 3% to 5% [17-23]. Both
types of rashes (zoster and varicella-like) were observed in
the 2 large zoster vaccination studies (Zostavax Efﬁcacy and
Safety Trial and Shingles Prevention Study). In both trials, the
skin rashes occurred in both the vaccine and placebo arms,
and the presence of the Oka strain could not be demon-
strated in any of these rashes. Most cases were due to wild-
type VZV occurring in both the placebo and vaccine arms
[10,15]. It is worth noting that our population is at a higher
risk for VZV reactivation compared with the general popu-
lation enrolled in both trials. It is also notable that no cases
of shingles have been identiﬁed to date in any of our vacci-
nated patients after the 42 day post-vaccination conven-
tional safety period; however, the follow-up time is limited.
This study has some limitations. VZV serology was not
performed before vaccination, and post-vaccination immune
responses and efﬁcacy were not directly assessed because
this study was observational in nature. Given the small
sample size, less common safety events would not be
detected. Longer follow-up is warranted to see if the vaccine
provided clinical efﬁcacy in patients who received it. Because
it remains unclear whether Varivax or Zostavax may be
better in HSCT recipients from a safety and immunogenicity
standpoint, further studies are warranted.
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